Cellular Ependymoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: CLL010 MIFTS: 59	Cellular Ependymoma Categories: Cancer diseases, Genetic diseases, Neuronal diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Cellular Ependymoma

MalaCards integrated aliases for Cellular Ependymoma:

Name: Cellular Ependymoma ¹¹ ¹⁹ ¹⁴ ⁷¹

Ependymoma ¹⁹ ⁵⁸ ⁷⁵ ²⁸ ⁵³ ⁵ ¹⁶ ⁷¹

Tanycytic Ependymoma ¹⁹ ⁷¹

Papillary Ependymoma ¹⁹ ⁷¹

Classic Ependymoma ¹⁹ ⁵⁸

Who Grade Ii Ependymal Neoplasm ¹⁹

Epithelial Ependymoma ¹⁹

Clear Cell Ependymoma ¹⁹

Ependymoma, Familial ¹⁹

Characteristics:

Prevelance:

Ependymoma: 1-9/1000000 (Europe) ⁵⁸

Age Of Onset:

Ependymoma: All ages ⁵⁸

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases Genetic diseases
Anatomical: Neuronal diseases

See all MalaCards categories (disease lists)

ICD10: ³²

Neoplasms

Neoplasms of uncertain or unknown behaviour

Neoplasm of uncertain or unknown behaviour of brain and central nervous system

Neoplasm of uncertain or unknown behaviour: Brain, unspecified

Orphanet: ⁵⁸

Rare neurological diseases

External Ids:

Disease Ontology ¹¹ DOID:5500

MeSH ⁴³ D004806

NCIt ⁴⁹ C4713

SNOMED-CT ⁶⁸ 57706008

ICD10 via Orphanet ³² D43.2

UMLS via Orphanet ⁷² C0014474

Orphanet ⁵⁸ ORPHA251636

EFO ¹⁶ EFO_1000028

UMLS ⁷¹ C0014474 C0334578 C1370500 more

Sources

Summaries for Cellular Ependymoma

Orphanet: ⁵⁸ Ependymoma is the most frequent intramedullary tumor in adults (but accounts for only 10-12% of pediatric central nervous system tumors), and can be benign or anaplastic. Ependymoma arise from the ependymal cells of the cerebral ventricles, corticle rests and central canal of the spinal cord, and manifest with variable symptoms such headache, vomiting, seizures, focal neurological signs and loss of vision and can cause obstructive hydrocephalus in some cases.

MalaCards based summary: Cellular Ependymoma, also known as ependymoma, is related to spinal cord ependymoma and childhood supratentorial ependymoma. An important gene associated with Cellular Ependymoma is MEN1 (Menin 1), and among its related pathways/superpathways are Neuroscience and DNA Damage. The drugs Carboplatin and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and liver, and related phenotypes are ependymoma and migraine

GARD: ¹⁹ Ependymomas are rare glial tumors of the brain and spinal cord (Yokota et al., 2003).

Wikipedia: ⁷⁵ An ependymoma is a tumor that arises from the ependyma, a tissue of the central nervous system. Usually,... more...

Sources

Related Diseases for Cellular Ependymoma

Diseases related to Cellular Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 596)

#	Related Disease	Score	Top Affiliating Genes
1	spinal cord ependymoma	32.6	ZFTA RELA NF2
2	childhood supratentorial ependymoma	32.5	ZFTA RELA
3	rela fusion-positive ependymoma	32.5	ZFTA RELA
4	posterior fossa ependymoma	32.4	ZFTA RELA
5	tanycytic ependymoma	32.3	ZFTA RELA NF2 MSH2 MEN1 GFAP
6	childhood ependymoma	32.1	ZFTA RELA
7	papillary ependymoma	31.9	SYP S100B NF2 MSH2 MEN1 GFAP
8	benign ependymoma	31.7	ZFTA SYP RELA NF2 GFAP
9	clear cell ependymoma	30.8	ZFTA VIM SYP RELA NF2 MUC1
10	cauda equina syndrome	30.6	SYP GFAP
11	spinal cancer	30.6	ZFTA NF2 GFAP
12	central neurocytoma	30.6	SYP NES GFAP
13	embryonal tumor with multilayered rosettes, c19mc-altered	30.4	SYP GFAP
14	obstructive hydrocephalus	30.4	SYP NF2 GFAP
15	pleomorphic xanthoastrocytoma	30.4	ZFTA SYP MGMT
16	supratentorial ependymoma	30.4	ZFTA RELA NF2
17	diffuse astrocytoma	30.3	MGMT GFAP EGFR
18	oligoastrocytoma	30.1	MGMT GFAP
19	subependymal giant cell astrocytoma	30.1	SYP S100B GFAP
20	medulloepithelioma	30.1	SYP NES GFAP
21	pineal gland cancer	30.1	SYP GFAP
22	ganglioglioma	30.1	SYP S100B NES GFAP
23	neurilemmoma	30.0	VIM SYP S100B NF2 NES MUC1
24	teratoma	30.0	VIM SYP NES MUC1 GFAP
25	carcinoid tumors, intestinal	30.0	SYP MEN1
26	chordoid meningioma	29.9	SYP NF2
27	ganglioneuroma	29.9	SYP S100B GFAP
28	mucinous adenocarcinoma	29.9	MUC1 MSH2 EGFR
29	astroblastoma	29.9	ZFTA VIM RELA GFAP
30	choroid plexus cancer	29.9	ZFTA SYP S100B GFAP
31	meningothelial meningioma	29.9	NF2 GFAP
32	rhabdoid meningioma	29.8	VIM SYP NF2 GFAP
33	low grade glioma	29.8	SYP NES MGMT GFAP EGFR
34	anaplastic oligodendroglioma	29.8	NES MGMT GFAP EGFR
35	clear cell meningioma	29.8	SYP NF2 GFAP
36	rhabdoid cancer	29.8	VIM SYP MUC1
37	hydrocephalus	29.7	SYP S100B NES GFAP
38	high grade ependymoma	29.7	ZFTA RELA NF2 MGMT GFAP
39	high grade glioma	29.7	NES MGMT HOTAIR GFAP EGFR
40	hemangioblastoma	29.7	VIM SYP S100B MUC1 GFAP EGFR
41	papilloma of choroid plexus	29.7	SYP S100B MUC1 LINC01194 GFAP
42	chordoma	29.7	VIM S100B MUC1 GFAP EGFR
43	cystic teratoma	29.7	SYP MUC1
44	glioblastoma	29.7	NF2 NES MSH2 MGMT HOTAIR GFAP
45	bap1 tumor predisposition syndrome	29.7	NF2 MSH2 MEN1 EGFR
46	gemistocytic astrocytoma	29.7	S100B MGMT GFAP
47	spinal cord disease	29.6	SYP NF2 NES MGMT GFAP EGFR
48	adrenal carcinoma	29.6	VIM SYP MEN1
49	ewing sarcoma	29.5	VIM SYP S100B NES
50	supratentorial primitive neuroectodermal tumor	29.5	SYP GFAP

Graphical network of the top 20 diseases related to Cellular Ependymoma:

Sources

Symptoms & Phenotypes for Cellular Ependymoma

Human phenotypes related to Cellular Ependymoma:

⁵⁸ ³⁰ (show all 15)

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	ependymoma ⁵⁸ ³⁰	Obligate (100%)	Obligate (100%)	HP:0002888
2	migraine ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0002076
3	pain ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0012531
4	abnormal cell morphology ⁵⁸ ³⁰	Frequent (33%)	Frequent (79-30%)	HP:0025461
5	seizure ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001250
6	gait disturbance ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0001288
7	vomiting ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002013
8	spinal cord tumor ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0010302
9	distal muscle weakness ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0002460
10	dysesthesia ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0012534
11	supratentorial neoplasm ⁵⁸ ³⁰	Occasional (7.5%)	Occasional (29-5%)	HP:0030693
12	neoplasm of the lung ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0100526
13	ovarian neoplasm ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0100615
14	neoplasm of the liver ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0002896
15	neoplasm of the breast ⁵⁸ ³⁰	Very rare (1%)	Very rare (<4-1%)	HP:0100013

GenomeRNAi Phenotypes related to Cellular Ependymoma according to GeneCards Suite gene sharing:

²⁵ (show all 27)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Increased shRNA abundance (Z-score > 2)	GR00366-A-111	9.78	MEN1
2	Increased shRNA abundance (Z-score > 2)	GR00366-A-116	9.78	MSH2
3	Increased shRNA abundance (Z-score > 2)	GR00366-A-121	9.78	EGFR
4	Increased shRNA abundance (Z-score > 2)	GR00366-A-122	9.78	TP73
5	Increased shRNA abundance (Z-score > 2)	GR00366-A-128	9.78	MEN1
6	Increased shRNA abundance (Z-score > 2)	GR00366-A-14	9.78	MSH2
7	Increased shRNA abundance (Z-score > 2)	GR00366-A-151	9.78	MSH2
8	Increased shRNA abundance (Z-score > 2)	GR00366-A-153	9.78	MEN1
9	Increased shRNA abundance (Z-score > 2)	GR00366-A-160	9.78	TIMP3
10	Increased shRNA abundance (Z-score > 2)	GR00366-A-166	9.78	TIMP3
11	Increased shRNA abundance (Z-score > 2)	GR00366-A-168	9.78	TIMP3
12	Increased shRNA abundance (Z-score > 2)	GR00366-A-176	9.78	MSH2
13	Increased shRNA abundance (Z-score > 2)	GR00366-A-199	9.78	TP73
14	Increased shRNA abundance (Z-score > 2)	GR00366-A-204	9.78	TP73
15	Increased shRNA abundance (Z-score > 2)	GR00366-A-208	9.78	TP73
16	Increased shRNA abundance (Z-score > 2)	GR00366-A-21	9.78	EGFR
17	Increased shRNA abundance (Z-score > 2)	GR00366-A-214	9.78	EGFR MSH2
18	Increased shRNA abundance (Z-score > 2)	GR00366-A-3	9.78	TIMP3
19	Increased shRNA abundance (Z-score > 2)	GR00366-A-43	9.78	EGFR TIMP3 TP73
20	Increased shRNA abundance (Z-score > 2)	GR00366-A-47	9.78	MEN1
21	Increased shRNA abundance (Z-score > 2)	GR00366-A-53	9.78	MSH2
22	Increased shRNA abundance (Z-score > 2)	GR00366-A-59	9.78	TIMP3
23	Increased shRNA abundance (Z-score > 2)	GR00366-A-67	9.78	TIMP3
24	Increased shRNA abundance (Z-score > 2)	GR00366-A-85	9.78	EGFR
25	Increased shRNA abundance (Z-score > 2)	GR00366-A-91	9.78	EGFR
26	Increased shRNA abundance (Z-score > 2)	GR00366-A-98	9.78	MEN1
27	Increased proliferation	GR00094-A	8.96	MEN1 NF2

MGI Mouse Phenotypes related to Cellular Ependymoma:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	normal	MP:0002873	10.02	EGFR GFAP MEN1 MKI67 MUC1 RELA
2	nervous system	MP:0003631	10	EGFR GFAP MEN1 MGMT MSH2 NES
3	homeostasis/metabolism	MP:0005376	10	EGFR GFAP MEN1 MGMT MKI67 MSH2
4	neoplasm	MP:0002006	9.97	EGFR MEN1 MGMT MKI67 MSH2 MUC1
5	digestive/alimentary	MP:0005381	9.56	EGFR GFAP MEN1 MSH2 MUC1 NF2
6	respiratory system	MP:0005388	9.23	EGFR MEN1 MGMT NF2 RELA TIMP3

Sources

Drugs & Therapeutics for Cellular Ependymoma

Drugs for Cellular Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 198)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Carboplatin

Approved

Phase 2, Phase 3

41575-94-4

10339178 38904

Etoposide

Approved

Phase 2, Phase 3

33419-42-0

36462

Cyclophosphamide

Approved, Investigational

Phase 2, Phase 3

50-18-0, 6055-19-2

2907

Temozolomide

Approved, Investigational

Phase 2, Phase 3

85622-93-1

5394

Thiotepa

Approved, Investigational

Phase 2, Phase 3

52-24-4

5453

Valproic acid

Approved, Investigational

Phase 2, Phase 3

99-66-1

3121

Cisplatin

Approved

Phase 3

15663-27-1

2767 5702198 441203

Vincristine

Approved, Investigational

Phase 3

2068-78-2, 57-22-7

5978

Picropodophyllin

Approved, Investigational

Phase 3

518-28-5, 477-47-4

10607 72435

Trofosfamide

Investigational

Phase 2, Phase 3

22089-22-1

65702

Antirheumatic Agents

Phase 2, Phase 3

Alkylating Agents

Phase 2, Phase 3

Antineoplastic Agents, Alkylating

Phase 2, Phase 3

Etoposide phosphate

Phase 2, Phase 3

16760419

Immunosuppressive Agents

Phase 2, Phase 3

Immunologic Factors

Phase 2, Phase 3

Psychotropic Drugs

Phase 2, Phase 3

Anticonvulsants

Phase 2, Phase 3

Antimitotic Agents

Phase 3

Keratolytic Agents

Phase 3

Tubulin Modulators

Phase 3

Lenograstim

Approved, Investigational

Phase 2

135968-09-1

Coenzyme M

Approved, Investigational

Phase 2

3375-50-6

598 23662354

Sunitinib

Approved, Investigational

Phase 2

557795-19-4

5329102

Sargramostim

Approved, Investigational

Phase 2

123774-72-1

Pemetrexed

Approved, Investigational

Phase 2

150399-23-8, 137281-23-3

60843 446556 135565230

Oxaliplatin

Approved, Investigational

Phase 2

61825-94-3

43805 11947679 6857599

Ivosidenib

Approved, Investigational

Phase 2

1448347-49-6

78140854 71657455

Lomustine

Approved, Investigational

Phase 2

13010-47-4

3950

Celecoxib

Approved, Investigational

Phase 2

169590-42-5

2662

Fenofibric acid

Approved

Phase 2

42017-89-0

64929

Cytarabine

Approved, Investigational

Phase 2

147-94-4

6253

Thalidomide

Approved, Investigational, Withdrawn

Phase 2

50-35-1

5426

Nivolumab

Approved

Phase 2

946414-94-4

Sirolimus

Approved, Investigational

Phase 2

53123-88-9

5284616 6436030

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 2

1177-87-3

3680

Dexamethasone

Approved, Investigational, Vet_approved

Phase 2

50-02-2

3003 5743

Irinotecan

Approved, Investigational

Phase 2

97682-44-5, 100286-90-6

60838

Palbociclib

Approved, Investigational

Phase 2

571190-30-2

5330286

Mebendazole

Approved, Vet_approved

Phase 2

31431-39-7

4030

Piperazine

Approved, Vet_approved

Phase 2

110-85-0

4837

Olaparib

Approved

Phase 2

763113-22-0

23725625

Carbamide peroxide

Approved

Phase 2

124-43-6

Acetaminophen

Approved

Phase 2

103-90-2

1983

Iodine

Approved, Investigational

Phase 2

7553-56-2

807

Ondansetron

Approved, Withdrawn

Phase 2

99614-02-5

4595

Histamine

Approved, Investigational

Phase 2

51-45-6

774

Diphenhydramine

Approved, Investigational

Phase 2

147-24-0, 58-73-1

3100

Promethazine

Approved, Investigational

Phase 2

60-87-7

4927

Vinblastine

Approved

Phase 2

865-21-4

241903 13342

Interventional clinical trials:

(show top 50) (show all 148)

#	Name	Status	NCT ID	Phase	Drugs
1	Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial	Unknown status	NCT00517959	Phase 3
2	Therapy-Optimization Trial and Phase II Study for the Treatment of Relapsed or Refractory of Primitive Neuroectodermal Brain Tumors and Ependymomas in Children and Adolescents	Completed	NCT00749723	Phase 2, Phase 3	carboplatin;etoposide;temozolomide;thiotepa, carboplatin, etoposide;temozolomide, thiotepa;intraventricular etoposide;trofosfamide, etoposide
3	An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma	Recruiting	NCT02265770	Phase 2, Phase 3	16 weeks of VEC + CDDP;VEC + HD-MTX;Chemotherapy + Valproate;VEC;Chemotherapy
4	Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years	Active, not recruiting	NCT01096368	Phase 3	Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Vincristine
5	Phase II Study of High-Dose Methotrexate in Children With Residual Ependymoma	Unknown status	NCT00287924	Phase 2	methotrexate
6	Phase II Study of Intravenous Etoposide in Patients With Relapsed Ependymoma	Unknown status	NCT00278252	Phase 2	etoposide
7	Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas	Unknown status	NCT01721577	Phase 1, Phase 2	AXL1717
8	A Phase II Trial of Conformal Radiation Therapy for Pediatric Patients With Localized Ependymoma, Chemotherapy Prior to Second Surgery for Incompletely Resected Ependymoma and Observation for Completely Resected, Differentiated, Supratentorial Ependymoma	Completed	NCT00027846	Phase 2	carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
9	Phase II Trial of Irinotecan in Children With Refractory Solid Tumors	Completed	NCT00004078	Phase 2	irinotecan hydrochloride
10	A Phase II Study of Sunitinib (NSC# 736511) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients	Completed	NCT01462695	Phase 2	Sunitinib Malate
11	A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage	Completed	NCT00492089	Phase 2	bevacizumab;placebo
12	Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial	Completed	NCT01295944	Phase 2	Carboplatin;Bevacizumab
13	A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma	Completed	NCT00826241	Phase 2	Temozolomide;Lapatinib
14	Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma	Completed	NCT00095940	Phase 1, Phase 2	lapatinib ditosylate
15	A Phase II Trial of Preradiation Multiagent Chemotherapy for Adults With "Poor Risk" Medulloblastoma, PNET, and Disseminated Ependymoma	Completed	NCT00003309	Phase 2	cisplatin;cyclophosphamide;etoposide;vincristine sulfate
16	A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma	Completed	NCT00883688	Phase 2	Bevacizumab;Lapatinib
17	Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation	Completed	NCT00006258	Phase 2	cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
18	SIOP Study of Combined Modality Treatment in Childhood Ependymoma	Completed	NCT00004224	Phase 2	cyclophosphamide;etoposide;vincristine sulfate
19	A Phase II Study of Pemetrexed in Children With Recurrent Malignancies	Completed	NCT00520936	Phase 2	pemetrexed
20	Phase 1/2 Study of Bempegaldesleukin in Combination With Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Malignancies (PIVOT IO 020)	Completed	NCT04730349	Phase 1, Phase 2
21	Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas	Completed	NCT00381797	Phase 2	Irinotecan Hydrochloride
22	Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas	Completed	NCT01125046	Phase 2
23	Proton Radiation for Low Grade Gliomas	Completed	NCT01024907	Phase 1, Phase 2
24	A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors	Completed	NCT00091182	Phase 2	oxaliplatin
25	A PHASE II TRIAL OF ETOPOSIDE AND CISPLATIN IN THE TREATMENT OF RECURRENT EPENDYMOMAS	Completed	NCT00002876	Phase 2	cisplatin;etoposide
26	CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy	Completed	NCT00008008	Phase 2	cyclophosphamide;thiotepa
27	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Tipifarnib in Patients With Tumors Harboring HRAS Genomic Alterations	Recruiting	NCT04284774	Phase 2	Tipifarnib
28	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients With Tumors Harboring IDH1 Mutations	Recruiting	NCT04195555	Phase 2	Ivosidenib
29	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations	Recruiting	NCT04320888	Phase 2	Selpercatinib
30	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients With Tumors Harboring Actionable NTRK Fusions	Recruiting	NCT03213704	Phase 2	Larotrectinib Sulfate
31	A Phase II Study of Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma, Ependymoma and ATRT	Recruiting	NCT01356290	Phase 2	Bevacizumab;Thalidomide;Celecoxib;Fenofibric acid;Etoposide;Cyclophosphamide;Etoposide phosphate;Cytarabine
32	Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2)	Recruiting	NCT04374305	Phase 2	Brigatinib;Neratinib
33	Methionine PET/CT Studies In Patients With Cancer	Recruiting	NCT00840047	Phase 2	Methionine
34	Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors	Recruiting	NCT03095248	Phase 2	Selumetinib
35	Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers	Recruiting	NCT03173950	Phase 2	Nivolumab
36	Phase 2 Trial of Indoximod With Chemotherapy and Radiation for Children With Progressive Brain Tumors or Newly Diagnosed DIPG	Recruiting	NCT04049669	Phase 2	Indoximod;Temozolomide;Cyclophosphamide;Etoposide;Lomustine
37	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol	Recruiting	NCT03155620	Phase 2	Ensartinib;Erdafitinib;Larotrectinib Sulfate;Olaparib;Palbociclib;Samotolisib;Selpercatinib;Selumetinib Sulfate;Tazemetostat;Tipifarnib;Ulixertinib;Vemurafenib
38	NCI-COG Pediatric MATCH (Molecular Analysis For Therapy Choice)- Phase 2 Subprotocol of LY3023414 in Patients With Solid Tumors	Recruiting	NCT03213678	Phase 2	Samotolisib
39	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Palbociclib in Patients With Tumors Harboring Activating Alterations in Cell Cycle Genes	Active, not recruiting	NCT03526250	Phase 2	Palbociclib
40	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- A Phase 2 Subprotocol of Olaparib in Patients With Tumors Harboring Defects in DNA Damage Repair Genes	Active, not recruiting	NCT03233204	Phase 2	Olaparib
41	Phase 2 Study of Intraventricular Omburtamab-based Radioimmunotherapy for Pediatric Patients With Recurrent Medulloblastoma and Ependymoma	Active, not recruiting	NCT04743661	Phase 2	Irinotecan;Temozolomide;Bevacizumab;Omburtamab I-131;Liothyronine;SSKI;Dexamethasone;Antipyretic;Antihistamine;anti-emetics
42	A Phase II Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma	Active, not recruiting	NCT02125786	Phase 2	^1^8F-Fluorodeoxyglucose;^1^1C-methionine
43	Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma	Active, not recruiting	NCT00602667	Phase 2	Induction Chemotherapy;Low-Risk Therapy;High-Risk Therapy;Intermediate-Risk Therapy
44	Phase II Study of Everolimus (RAD001, Afinitor®) for Children With Recurrent or Progressive Ependymoma	Active, not recruiting	NCT02155920	Phase 2	Everolimus
45	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of BVD-523FB (Ulixertinib) in Patients With Tumors Harboring Activating MAPK Pathway Mutations	Active, not recruiting	NCT03698994	Phase 2	Ulixertinib
46	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex	Active, not recruiting	NCT03213665	Phase 2	Tazemetostat
47	Memantine for Prevention of Cognitive Late Effects in Pediatric Patients Receiving Cranial Radiation Therapy for Localized Brain Tumors: A Pilot Study	Active, not recruiting	NCT03194906	Phase 2	Memantine
48	NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 Subprotocol of Vemurafenib in Patients With Tumors Harboring BRAF V600 Mutations	Active, not recruiting	NCT03220035	Phase 2	Vemurafenib
49	A Phase II Study of Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation: An Assessment of Long Term Neurocognitive, Neuroendocrine Adn Ototoxicity Outcomes	Active, not recruiting	NCT01288235	Phase 2
50	Phase I/II Study of Lutathera in Pediatric and Young Adult Patients With Recurrent and/or Progressive High-Grade Central Nervous System Tumors and Meningiomas That Express Somatostatin Type2A Receptors and Demonstrate Uptake on DOTATATE PET	Not yet recruiting	NCT05278208	Phase 1, Phase 2	LUTATHERA® (Lutetium Lu 177 dotatate)

Search NIH Clinical Center for Cellular Ependymoma

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Carmustine

Sources

Genetic Tests for Cellular Ependymoma

Genetic tests related to Cellular Ependymoma:

#	Genetic test	Affiliating Genes
1	Ependymoma ²⁸

Sources

Anatomical Context for Cellular Ependymoma

Organs/tissues related to Cellular Ependymoma:

MalaCards : Spinal Cord, Brain, Liver, T Cells, Breast, Lung, Nk Cells

Sources

Publications for Cellular Ependymoma

Articles related to Cellular Ependymoma:

(show top 50) (show all 4283)

#	Title	Authors	PMID	Year
1	Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors. ⁵³ ⁶²	Sardi I...Arico M	19724855	2009
2	Podoplanin is a potential marker for the diagnosis of ependymoma: a comparative study with epithelial membrane antigen (EMA). ⁵³ ⁶²	Ishizawa K...Hirose T	19788053	2009
3	[Expression of epidermal growth factor receptor and Ki-67 antigen in brain ependymoma and the correlation between them]. ⁵³ ⁶²	Cui Y...Zhao JZ	19257969	2008
4	EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts. ⁵³ ⁶²	Geoerger B...Vassal G	18386816	2008
5	Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors. ⁵³ ⁶²	Ishizawa K...Hirose T	18552083	2008
6	Nestin expression in different tumours and its relevance to malignant grade. ⁵³ ⁶²	Yang XH...Xiang AP	17873113	2008
7	Immunohistochemical study of CD99 and EMA expression in ependymomas. ⁵³ ⁶²	Mahfouz S...el-Sheikh S	18382710	2008
8	Frequent but borderline methylation of p16 (INK4a) and TIMP3 in medulloblastoma and sPNET revealed by quantitative analyses. ⁵³ ⁶²	Muhlisch J...Fruhwald MC	17206475	2007
9	New immunohistochemical markers in the evaluation of central nervous system tumors: a review of 7 selected adult and pediatric brain tumors. ⁵³ ⁶²	Takei H...Powell SZ	17284108	2007
10	Immunohistochemical profile and chromosomal imbalances in papillary tumours of the pineal region. ⁵³ ⁶²	Hasselblatt M...Paulus W	16640646	2006
11	p53 Pathway dysfunction in primary childhood ependymomas. ⁵³ ⁶²	Gaspar N...Vassal G	16086408	2006
12	Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. ⁵³ ⁶²	Mendrzyk F...Lichter P	16609018	2006
13	Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. ⁵³ ⁶²	Michalowski MB...Plantaz D	16616114	2006
14	Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome. ⁵³ ⁶²	Preusser M...Hainfellner JA	16146813	2005
15	Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma. ⁵³ ⁶²	Hamilton DW...Clifford SC	16051033	2005
16	A PDGFRA promoter polymorphism, which disrupts the binding of ZNF148, is associated with primitive neuroectodermal tumours and ependymomas. ⁵³ ⁶²	De Bustos C...Afink G	15635072	2005
17	Light microscopic demonstration of the microlumen of ependymoma: a study of the usefulness of antigen retrieval for epithelial membrane antigen (EMA) immunostaining. ⁵³ ⁶²	Kawano N...Yamashina S	15696964	2004
18	Sensitivity and specificity of epithelial membrane antigen staining patterns in ependymomas. ⁵³ ⁶²	Hasselblatt M...Paulus W	12898159	2003
19	March 2003: a 41 -year-old female with a solitary lesion in the liver. ⁵³ ⁶²	Wiendl H...Weller M	12946033	2003
20	Complex cytogenetic abnormalities including telomeric associations and MEN1 mutation in a pediatric ependymoma. ⁵³ ⁶²	Urioste M...Benitez J	12505253	2002
21	The expression of p73, p21 and MDM2 proteins in gliomas. ⁵³ ⁶²	Kamiya M...Nakazato Y	12241107	2002
22	Immunohistochemical markers for prognosis of ependymal neoplasms. ⁵³ ⁶²	Korshunov A...Timirgaz V	12187959	2002
23	Differential involvement of protein 4.1 family members DAL-1 and NF2 in intracranial and intraspinal ependymomas. ⁵³ ⁶²	Singh PK...Perry A	12011257	2002
24	Analysis of the NF2 gene in oligodendrogliomas and ependymomas. ⁵³ ⁶²	Alonso ME...Rey JA	11996787	2002
25	p14ARF protein (FL-132) immunoreactivity in intracranial ependymomas and its prognostic significance: an analysis of 103 cases. ⁵³ ⁶²	Korshunov A...Timirgaz V	11585252	2001
26	Telomerase activity and expression of telomerase reverse transcriptase correlated with cell proliferation in meningiomas and malignant brain tumors in vivo. ⁵³ ⁶²	Cabuy E...de Ridder L	11561758	2001
27	Mutation analysis of the p73 gene in nonastrocytic brain tumours. ⁵³ ⁶²	Alonso ME...Rey JA	11461077	2001
28	Molecular genetic alterations on chromosomes 11 and 22 in ependymomas. ⁵³ ⁶²	Lamszus K...Westphal M	11275983	2001
29	Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases. ⁵³ ⁶²	Korshunov A...Timirgaz V	10967185	2000
30	Receptor-mediated endocytosis of transthyretin by ependymoma cells. ⁵³ ⁶²	Kuchler-Bopp S...Delaunoy JP	10869517	2000
31	The immunophenotype of ependymomas. ⁵³ ⁶²	Vege KD...Scheithauer BW	10937045	2000
32	Low frequency of SV40, JC and BK polyomavirus sequences in human medulloblastomas, meningiomas and ependymomas. ⁵³ ⁶²	Weggen S...Pietsch T	10668898	2000
33	Ovarian ependymoma. A case report. ⁵³ ⁶²	Garcia-Barriola V...Garcia-Tamayo J	10982025	2000
34	Evidence for an ependymoma tumour suppressor gene in chromosome region 22pter-22q11.2. ⁵³ ⁶²	Hulsebos TJ...Tijssen CC	10584875	1999
35	Expression of the simian virus 40 large tumor antigen (Tag) and formation of Tag-p53 and Tag-pRb complexes in human brain tumors. ⁵³ ⁶²	Zhen HN...Wang XL	10570441	1999
36	Atypical central neurocytoma: report of a case. ⁵³ ⁶²	Chou YY...Wei CP	10502912	1999
37	Cerebellar papillary meningioma in a 3-year-old boy: the usefulness of electron microscopy for diagnosis. ⁵³ ⁶²	Bouvier C...Figarella-Branger D	10403309	1999
38	Molecular genetic analysis of non-astrocytic gliomas. ⁵³ ⁶²	Tong CY...Lee JC	10231401	1999
39	Signet-ring cell ependymoma: case report with implications for pathogenesis and differential diagnosis. ⁵³ ⁶²	Vajtai I...Bodi I	10631722	1999
40	Tissue culture of human neurocytomas induces the expression of glial fibrilary acidic protein. ⁵³ ⁶²	Westphal M...Herrmann HD	10451427	1998
41	O6-Methylguanine-DNA methyltransferase protein levels in pediatric brain tumors. ⁵³ ⁶²	Hongeng S...Heideman RL	9815647	1997
42	Expression of telomerase RNA component correlates with the MIB-1 proliferation index in ependymomas. ⁵³ ⁶²	Rushing EJ...Gazdar AF	9329458	1997
43	Paraganglioma of the cauda equina. A case report and review of the literature. ⁵³ ⁶²	Bak J...Spannare B	8611199	1996
44	The ultrastructure of ependymoma: personal experience and the review of the literature. ⁵³ ⁶²	Liberski PP	9812425	1996
45	Loss of heterozygosity on chromosome 10, 13q(Rb), 17p, and p53 gene mutations in human brain gliomas. ⁵³ ⁶²	Lee SH...Choi KS	8924230	1995
46	Expression of non-glial intermediate filament proteins in gliomas. ⁵³ ⁶²	Hirato J...Ogawa A	7518371	1994
47	Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material. ⁵³ ⁶²	Karamitopoulou E...Maraziotis T	7511316	1994
48	Cauda equina tumor with ependymal and paraganglionic differentiation. ⁵³ ⁶²	Caccamo DV...Garcia JH	1612583	1992
49	Epidermal growth factor receptor in human brain tumors. ⁵³ ⁶²	Di Carlo A...Macchia V	1560188	1992
50	[Immunohistochemical study for choroid plexus papillomas and ependymomas]. ⁵³ ⁶²	Kunishio K...Taguchi K	1726244	1991

Sources

Genes for Cellular Ependymoma

Genes related to Cellular Ependymoma (3 elite genes):

(show all 18)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	MEN1	Menin 1	Protein Coding	404.12	Pathogenic ⁵ Novoseek inferred ⁵³	12505253 11275983
2	ZFTA	Zinc Finger Translocation Associated	Protein Coding	355.65	Gene fusion ⁵⁸ DISEASES inferred ¹⁴	24553141
3	RELA	RELA Proto-Oncogene, NF-KB Subunit	Protein Coding	354.24	Gene fusion ⁵⁸ DISEASES inferred ¹⁴	24553141
4	HOTAIR	HOX Transcript Antisense RNA	RNA Gene	150	Experimental evidence: Regulation ³⁷	25085602
5	NF2	NF2, Moesin-Ezrin-Radixin Like (MERLIN) Tumor Suppressor	Protein Coding	34.23	Likely pathogenic ⁵ Novoseek inferred ⁵³	12011257 10433955 17509660 (more) 9100669 11996787 15731777 9222206 9537418 15072463 10584875
6	MSH2	MutS Homolog 2	Protein Coding	25	Likely pathogenic ⁵
7	SYP	Synaptophysin	Protein Coding	13.68	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10502912 17284108 18360284 (more) 1612583 8611199 16640646 17061076
8	GFAP	Glial Fibrillary Acidic Protein	Protein Coding	13.22	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7754745 1695040 10937045 (more) 18360284 1726244 2187587 10982025 12946033 9812425 7518371 10451427
9	NES	Nestin	Protein Coding	9.52	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17873113
10	MGMT	O-6-Methylguanine-DNA Methyltransferase	Protein Coding	9.51	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	18467255 15072463 16051033 (more) 19724855 9815647 12850376
11	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	8.75	Novoseek inferred ⁵³	18382710 19788053 1726244 (more) 12898159 16640646 15696964 10631722 1695040 18360284 17284108 18552083 7666055
12	S100B	S100 Calcium Binding Protein B	Protein Coding	8.08	Novoseek inferred ⁵³	1726244 10937045
13	LINC01194	Long Intergenic Non-Protein Coding RNA 1194	RNA Gene	7.85	Novoseek inferred ⁵³	10668898 11780459 10570441
14	VIM	Vimentin	Protein Coding	7.85	Novoseek inferred ⁵³	8213089 10403309 7518371
15	EGFR	Epidermal Growth Factor Receptor	Protein Coding	5.75	Novoseek inferred ⁵³	19257969 16609018 12187959 (more) 20175962 18386816 1560188 8568531 1776845 7815080 1320666 10967185
16	MKI67	Marker Of Proliferation Ki-67	Protein Coding	5.36	Novoseek inferred ⁵³	7511316 16146813
17	TP73	Tumor Protein P73	Protein Coding	5.2	Novoseek inferred ⁵³	10213163 12241107 11461077 (more) 15072463 16051033
18	TIMP3	TIMP Metallopeptidase Inhibitor 3	Protein Coding	4.98	Novoseek inferred ⁵³	15072463 16051033 17206475

Sources

Variations for Cellular Ependymoma

ClinVar genetic disease variations for Cellular Ependymoma:

⁵ (show all 36)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	MEN1	NM_001370259.2(MEN1):c.696dup (p.Lys233fs)	DUP	Pathogenic	487778	rs1555165565	GRCh37: 11:64575111-64575111 GRCh38: 11:64807638-64807639
2	NF2	NM_000268.4(NF2):c.551G>A (p.Trp184Ter)	SNV	Likely Pathogenic	487796	rs1555993293	GRCh37: 22:30051617-30051617 GRCh38: 22:29655628-29655628
3	MSH2	NM_000251.3(MSH2):c.482T>C (p.Val161Ala)	SNV	Likely Pathogenic	565544	rs63750126	GRCh37: 2:47637348-47637348 GRCh38: 2:47410209-47410209
4	overlap with 76 genes	dup(11)(q13.1q13.1)	DUP	Likely Pathogenic	634998		GRCh37: 11:63533279-65429676 GRCh38:
5	POU3F4	NM_000307.5(POU3F4):c.1013C>T (p.Pro338Leu)	SNV	Uncertain Significance	487785	rs1555984638	GRCh37: X:82764345-82764345 GRCh38: X:83509337-83509337
6	KREMEN2	NM_172229.3(KREMEN2):c.494G>T (p.Gly165Val)	SNV	Uncertain Significance	487788	rs1210829529	GRCh37: 16:3016650-3016650 GRCh38: 16:2966649-2966649
7	HSD3B2	NM_000198.4(HSD3B2):c.1004G>A (p.Arg335Gln)	SNV	Uncertain Significance	487802	rs985808078	GRCh37: 1:119965128-119965128 GRCh38: 1:119422505-119422505
8	TRAF3	NM_145725.3(TRAF3):c.53C>G (p.Pro18Arg)	SNV	Uncertain Significance	487799	rs145456077	GRCh37: 14:103336591-103336591 GRCh38: 14:102870254-102870254
9	GON4L	NM_001282860.2(GON4L):c.2455A>G (p.Asn819Asp)	SNV	Uncertain Significance	487779	rs1553200563	GRCh37: 1:155742897-155742897 GRCh38: 1:155773106-155773106
10	ARHGAP32	NM_001378024.1(ARHGAP32):c.4745C>G (p.Thr1582Ser)	SNV	Uncertain Significance	487793	rs749174548	GRCh37: 11:128840363-128840363 GRCh38: 11:128970468-128970468
11	NET1	NM_001047160.3(NET1):c.498G>T (p.Glu166Asp)	SNV	Uncertain Significance	487790	rs1554818513	GRCh37: 10:5494455-5494455 GRCh38: 10:5452492-5452492
12	CACNG2	NM_006078.5(CACNG2):c.541T>C (p.Tyr181His)	SNV	Uncertain Significance	487807	rs1555892196	GRCh37: 22:36960829-36960829 GRCh38: 22:36564782-36564782
13	TRPM1	NM_001252024.2(TRPM1):c.283A>C (p.Ile95Leu)	SNV	Uncertain Significance	487810	rs1555424877	GRCh37: 15:31360292-31360292 GRCh38: 15:31068089-31068089
14	KAT6B	NM_012330.4(KAT6B):c.3827C>T (p.Pro1276Leu)	SNV	Uncertain Significance	487787	rs1554845417	GRCh37: 10:76788409-76788409 GRCh38: 10:75028651-75028651
15	TXNRD2	NM_006440.5(TXNRD2):c.1432G>C (p.Ala478Pro)	SNV	Uncertain Significance	487801	rs1555906972	GRCh37: 22:19865626-19865626 GRCh38: 22:19878103-19878103
16	SETD9	NM_153706.4(SETD9):c.788_796del (p.Ile263_Tyr265del)	DEL	Uncertain Significance	487781	rs1554039146	GRCh37: 5:56210766-56210774 GRCh38: 5:56914939-56914947
17	TASOR	NM_001365635.2(TASOR):c.97G>A (p.Glu33Lys)	SNV	Uncertain Significance	487784	rs1553733337	GRCh37: 3:56716938-56716938 GRCh38: 3:56682910-56682910
18	VBP1	NM_003372.7(VBP1):c.331C>A (p.Leu111Met)	SNV	Uncertain Significance	487792	rs1000821034	GRCh37: X:154456711-154456711 GRCh38: X:155228429-155228429
19	KLHL21	NM_014851.4(KLHL21):c.501G>C (p.Glu167Asp)	SNV	Uncertain Significance	487795	rs1292721663	GRCh37: 1:6662377-6662377 GRCh38: 1:6602317-6602317
20	MAP4K3	NM_003618.4(MAP4K3):c.899T>C (p.Phe300Ser)	SNV	Uncertain Significance	487798	rs1268580645	GRCh37: 2:39552678-39552678 GRCh38: 2:39325537-39325537
21	RET	NM_020975.6(RET):c.1202G>A (p.Ser401Asn)	SNV	Uncertain Significance	620604	rs1564493414	GRCh37: 10:43604617-43604617 GRCh38: 10:43109169-43109169
22	SYNE1	NM_182961.4(SYNE1):c.11097C>G (p.Phe3699Leu)	SNV	Uncertain Significance	487805	rs1554520414	GRCh37: 6:152674554-152674554 GRCh38: 6:152353419-152353419
23	BANP	NM_001386991.1(BANP):c.692A>G (p.Asn231Ser)	SNV	Uncertain Significance	487782	rs1555586650	GRCh37: 16:88052070-88052070 GRCh38: 16:88018464-88018464
24	SH3TC2	NM_024577.4(SH3TC2):c.3016del (p.Ser1006fs)	DEL	Uncertain Significance	487808	rs1554121513	GRCh37: 5:148406172-148406172 GRCh38: 5:149026609-149026609
25	SPRY3	NM_001304990.2(SPRY3):c.55C>T (p.Arg19Cys)	SNV	Uncertain Significance	487791	rs779201129	GRCh37: Y:59106594-59106594 GRCh38: X:155773926-155773926
26	OTUD5	NM_001136157.2(OTUD5):c.1687C>A (p.Pro563Thr)	SNV	Uncertain Significance	487794	rs1295653938	GRCh37: X:48780465-48780465 GRCh38: X:48923188-48923188
27	GLB1	NM_000404.4(GLB1):c.1903G>C (p.Ala635Pro)	SNV	Uncertain Significance	487803	rs1553604701	GRCh37: 3:33038668-33038668 GRCh38: 3:32997176-32997176
28	HDAC3	NM_003883.4(HDAC3):c.50_55+5del	DEL	Uncertain Significance	487780	rs1554218152	GRCh37: 5:141016298-141016308 GRCh38: 5:141636731-141636741
29	LETM1	NM_012318.3(LETM1):c.286G>A (p.Val96Met)	SNV	Uncertain Significance	487800	rs753905629	GRCh37: 4:1843382-1843382 GRCh38: 4:1841655-1841655
30	LATS1	NM_004690.4(LATS1):c.2365G>C (p.Asp789His)	SNV	Uncertain Significance	487797	rs750318192	GRCh37: 6:150001239-150001239 GRCh38: 6:149680103-149680103
31	ADGRA2	NM_032777.10(ADGRA2):c.1316_1334del (p.Asn439fs)	DEL	Uncertain Significance	487806	rs1554525957	GRCh37: 8:37691223-37691241 GRCh38: 8:37833705-37833723
32	SUV39H1	NM_003173.4(SUV39H1):c.415C>T (p.Arg139Cys)	SNV	Uncertain Significance	487783	rs368779259	GRCh37: X:48558731-48558731 GRCh38: X:48700340-48700340
33	SLC39A11	NM_139177.4(SLC39A11):c.595G>T (p.Val199Phe)	SNV	Uncertain Significance	487809	rs745762301	GRCh37: 17:70845779-70845779 GRCh38: 17:72849640-72849640
34	DEPDC5	NM_001242896.3(DEPDC5):c.2939G>A (p.Trp980Ter)	SNV	Uncertain Significance	487789	rs1555900957	GRCh37: 22:32241141-32241141 GRCh38: 22:31845155-31845155
35	PATZ1	NM_014323.3(PATZ1):c.562G>T (p.Asp188Tyr)	SNV	Uncertain Significance	487786	rs1555894069	GRCh37: 22:31741027-31741027 GRCh38: 22:31345041-31345041
36	MT-ND4	NC_012920.1:m.11032delA	DEL	Uncertain Significance	487804	rs1556423884	GRCh37: MT:11032-11032 GRCh38: MT:11032-11032

Copy number variations for Cellular Ependymoma from CNVD:

⁶ (show top 50) (show all 1024)

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	13823	1	1	7200000	Deletion		Ependymoma
2	15495	1	116080654	116108285	Amplification	NHLH2	Ependymoma
3	15648	1	117745152	117779348	Deletion	MAN1A2	Ependymoma
4	19381	1	150034000	245120000	Amplification		Ependymoma
5	19382	1	150034000	245120000	Amplification		Ependymoma
6	26308	1	198898833	198920273	Amplification	LGR6	Ependymoma
7	31595	1	2869431	2902617	Amplification	TLR5	Ependymoma
8	31803	1	3118000	5001000	Deletion		Ependymoma
9	38299	10	101279725	101300855	Deletion		Ependymoma
10	38453	10	102724768	102752246	Deletion	LZTS2	Ependymoma
11	38454	10	102724768	102752246	Deletion	MRPL43	Ependymoma
12	38455	10	102724768	102752246	Deletion	TWNK	Ependymoma
13	38456	10	102724768	102752246	Deletion	SEMA4G	Ependymoma
14	38866	10	105634726	105742493	Deletion	STN1	Ependymoma
15	38867	10	105634726	105742493	Deletion	SLK	Ependymoma
16	38979	10	106855945	106907237	Deletion	SORCS3	Ependymoma
17	39169	10	11151805	11236375	Deletion	CELF2	Ependymoma
18	40763	10	13344307	13497936	Deletion	PHYH	Ependymoma
19	40764	10	13344307	13497936	Deletion	SEPHS1	Ependymoma
20	40806	10	133827559	133847021	Amplification	JAKMIP3	Ependymoma
21	40809	10	133852261	133910912	Deletion	DPYSL4	Ependymoma
22	40810	10	133852261	133910912	Deletion	STK32C	Ependymoma
23	40887	10	134410586	134892955	Deletion	CFAP46	Ependymoma
24	40888	10	134410586	134892955	Deletion	CFAP46	Ependymoma
25	40889	10	134410586	134892955	Deletion	ADGRA1	Ependymoma
26	40890	10	134410586	134892955	Deletion	INPP5A	Ependymoma
27	40891	10	134410586	134892955	Deletion	KNDC1	Ependymoma
28	40892	10	134410586	134892955	Deletion		Ependymoma
29	41033	10	135073302	135095235	Amplification	ECHS1	Ependymoma
30	41034	10	135073302	135095235	Amplification	PAOX	Ependymoma
31	41074	10	135176625	135276748	Deletion	CYP2E1	Ependymoma
32	41075	10	135176625	135276748	Deletion	SPRNP1	Ependymoma
33	41076	10	135176625	135276748	Deletion	SYCE1	Ependymoma
34	41910	10	25665327	25756077	Deletion	GPR158	Ependymoma
35	42307	10	3169189	3180797	Deletion	PITRM1	Ependymoma
36	44077	10	5175582	5187881	Deletion	AKR1C8	Ependymoma
37	44224	10	53651276	53712562	Deletion	PRKG1	Ependymoma
38	44704	10	6170011	6268419	Deletion	RBM17	Ependymoma
39	45199	10	68970214	69114993	Deletion	CTNNA3	Ependymoma
40	45273	10	69645873	69701073	Deletion	ATOH7	Ependymoma
41	45408	10	70846341	70896472	Deletion	TSPAN15	Ependymoma
42	45468	10	71234506	71351772	Deletion	COL13A1	Ependymoma
43	45538	10	71990162	72295747	Deletion	ADAMTS14	Ependymoma
44	45539	10	71990162	72295747	Deletion	TBATA	Ependymoma
45	45540	10	71990162	72295747	Deletion	PALD1	Ependymoma
46	45541	10	71990162	72295747	Deletion	PRF1	Ependymoma
47	45542	10	71990162	72295747	Deletion	SGPL1	Ependymoma
48	45578	10	72636128	72774965	Deletion	SLC29A3	Ependymoma
49	45579	10	72636128	72774965	Deletion	UNC5B	Ependymoma
50	45628	10	73121579	73231404	Deletion	VSIR	Ependymoma

Sources

Expression for Cellular Ependymoma

Search GEO for disease gene expression data for Cellular Ependymoma.

Sources

Pathways for Cellular Ependymoma

Pathways related to Cellular Ependymoma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Neuroscience ³	12.09	SYP S100B NF2 MKI67 GFAP
2	DNA Damage ³	11.82	VIM TP73 MSH2 MKI67 MGMT
3	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ⁶¹ Nuclear signaling by ERBB4 ⁶⁶	11.67	S100B GFAP EGFR
4	Direct p53 effectors ⁶¹	11.6	TP73 MSH2 EGFR
5	Spinal cord injury ⁷⁴	11.49	VIM GFAP EGFR
6	Neural Stem Cells and Lineage-specific Markers ⁶⁵	10.92	VIM SYP S100B NES GFAP